![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/aardvark-therapeutics-announces-85-million-oversubscribed-series-c-financing-302140094.html
https://endpts.com/aardvark-raises-85m-to-target-hunger-not-appetite-as-it-contemplates-ipo-pharma-deals/
https://www.globenewswire.com//news-release/2023/08/23/2730472/0/en/GRI-Bio-Enters-into-Asset-Purchase-Agreement-with-Aardvark-Therapeutics-Inc-for-the-Sale-of-Legacy-Asset-ADAIR.html
https://www.prnewswire.com/news-releases/aardvark-therapeutics-announces-receipt-of-fda-rare-pediatric-disease-designation-for-prader-willi-syndrome-and-expands-the-ongoing-phase-2-clinical-trial-301892147.html
https://www.prnewswire.com/news-releases/aardvark-therapeutics-announces-fda-orphan-drug-designation-granted-to-ard-101-a-novel-drug-candidate-for-prader-willi-syndrome-301853812.html
https://www.clinicaltrialsarena.com/news/aardvark-therapeutics-ard-101/
https://www.prnewswire.com/news-releases/aardvark-therapeutics-reports-positive-phase-ii-clinical-data-for-ard-101-301848268.html
https://www.prnewswire.com/news-releases/aardvark-therapeutics-inc-announces-the-initiation-of-enrollment-for-three-phase-2-clinical-trials-of-oral-ard-101-301473522.html